Dr. de la Calle is the Chief Business Officer for Eutilex where he negotiated the license of EU101, the preclinical anti-4-1BB mAb for China to Zhejiang Huahai Pharmaceutical Ltd., receiving over $30M upfront in licensing and equity investment.
Most recently he was working for the South Korean government supporting Korean pharmaceutical companies for success in USA and Europe. Earlier as head of business development at Innate Pharma, S.A. (France), he was involved in deals that supported the company’s successful IPO. He was Director of business development at Micromet (now Amgen) licensing the scFv IP, essential for the BiTE (e.g. Blinatumomab).
Dr. de la Calle received his M.S. in physics from the Free University of Berlin. His Ph.D. was awarded from the Free University of Berlin in biochemistry after having performed his research at Harvard Medical School. He conducted his postdoctoral and business studies at the MIT.